3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Colorectal Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Large B-Cell, Diffuse
2
Lung Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma, Extra-Adrenal
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Osteosarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Lymphoma
1
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
1
Gynecological Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Diseases
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Methotrexate
21
Ifosfamide
21
Cyclophosphamide
19
Doxorubicin
17
Cisplatin
14
Filgrastim
13
Gemcitabine
12
Etoposide
11
Leucovorin
9
apatinib
8
fludarabine
7
glucarpidase
6
Vincristine
6
Temozolomide
6
Radiotherapy
6
Nivolumab
6
Neoadjuvant Therapy
6
Drug Therapy
6
Carboplatin
6
regorafenib
5
cabozantinib
5
Zoledronic Acid
5
Topotecan
5
Mesna
5
Irinotecan
5
Granulocyte Colony-Stimulating Factor
5
Docetaxel
5
pembrolizumab
4
pegfilgrastim
4
camrelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Osteosarcoma
×
penpulimab
×
Clear all
NCT06114225
2023-11-02
PROMIS
Ruijin Hospital
Phase 2
Recruiting
43 enrolled